Bone-targeted therapy in early breast cancer

Abstract

Aromatase inhibitors (AIs) play an important role in the adjuvant treatment of hormone receptor–positive breast cancer, but they are associated with bone loss and increased fracture risk. Although several guidelines for the management of osteoporosis and osteopenia exist, their algorithms do not account for the use of AIs. In this article, we describe the role of bone-targeted therapies, specifically for managing early breast cancer, by reviewing their bone-specific and cancer-specific benefits.